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Objectives The aim of this study was to develop a clinical model predictive of in-hospital mortality in a broad hospitalized
heart failure (HF) patient population.
Background Heart failure patients experience high rates of hospital stays and poor outcomes. Although predictors of mortal-
ity have been identified in HF clinical trials, hospitalized patients might differ greatly from trial populations, and
such predictors might underestimate mortality in a real-world population.
Methods The OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Fail-
ure) is a registry/performance improvement program for patients hospitalized with HF in 259 U.S. hospitals.
Forty-five potential predictor variables were used in a stepwise logistic regression model for in-hospital mortality.
Continuous variables that did not meet linearity assumptions were transformed. All significant variables (p 
0.05) were entered into multivariate analysis. Generalized estimating equations were used to account for the
correlation of data within the same hospital in the adjusted models.
Results Of 48,612 patients enrolled, mean age was 73.1 years, 52% were women, 74% were Caucasian, and 46% had
ischemic etiology. Mean left ventricular ejection fraction was 0.39  0.18. In-hospital mortality occurred in
1,834 (3.8%). Multivariable predictors of mortality included age, heart rate, systolic blood pressure (SBP), so-
dium, creatinine, HF as primary cause of hospitalization, and presence/absence of left ventricular systolic dys-
function. A scoring system was developed to predict mortality.
Conclusions Risk of in-hospital mortality for patients hospitalized with HF remains high and is increased in patients who are
older and have low SBP or sodium levels and elevated heart rate or creatinine at admission. Application of this
risk-prediction algorithm might help identify patients at high risk for in-hospital mortality who might benefit from
aggressive monitoring and intervention. (Organized Program to Initiate Lifesaving Treatment In Hospitalized Pa-
tients With Heart Failure [OPTIMIZE-HF]; NCT00344513) (J Am Coll Cardiol 2008;52:347–56) © 2008 by the
American College of Cardiology Foundation
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Predictors of HF Hospital Mortality in the OPTIMIZE-HF Trial July 29, 2008:347–56Acute decompensated heart fail-
ure (HF) requiring hospitaliza-
tion is common and has been
steadily increasing: in 2004, there
were more than 1 million HF
discharges in the U.S., an in-
crease of 175% since 1979 (1).
Despite the prevalence of acute
HF, research efforts over the last
15 years have focused primarily
on chronic HF. As a result, few
studies have been conducted spe-
cifically in the hospitalized HF
population, and data describing
linical characteristics and outcomes for these patients have
een lacking.
The increasing incidence and associated morbidity and
ortality of acute HF create an urgent need to better
nderstand this patient population. Because risk-prediction
odels are useful for focusing on factors influencing clinical
utcomes, several analyses have been conducted to deter-
ine mortality risk after hospitalization for HF, with both
linical trial and administrative databases (2–7). Clinical
rial datasets have contributed valuable information, but
heir general applicability is limited because these trials
eflect a select patient group and the findings of risk-
rediction models generated from these databases might or
ight not apply to a broader population (8). Whereas
dministrative datasets might not adequately capture clinical
ariables of prognostic importance, observational registries
re a useful data source for evaluating event rates and
eveloping risk-prediction models across a representative
atient spectrum. With this in mind, an analysis of the
PTIMIZE-HF (Organized Program to Initiate Lifesav-
ng Treatment in Hospitalized Patients with Heart Failure)
egistry database was conducted to identify predictors of
n-hospital mortality in a large, unselected sample of ob-
erved patients hospitalized with HF and to develop a
ractical risk-prediction tool that could be applied in routine
linical practice.
ethods
he OPTIMIZE-HF registry is a national hospital-based
egistry and quality-improvement program conducted in
59 hospitals across the U.S. The rationale and design have
een discussed in detail elsewhere and will be summarized
ere (9–11). The primary objective of the program was to
mprove medical care and education given to HF patients by
ccelerating the initiation of evidence-based, guideline-
ecommended HF therapies. The OPTIMIZE-HF registry
ombined a web-based registry data collection tool with a
rocess-of-care intervention that included standing orders,
lgorithms, and care paths that encouraged the use of
vidence-based therapies for all eligible patients (9). The
Abbreviations
and Acronyms
CART  classification and
regression tree
HF  heart failure
LVEF  left ventricular
ejection fraction
LVSD  left ventricular
systolic dysfunction
SBP  systolic blood
pressure
SCr  serum creatinineeb-based registry collected data on all Joint Commission on sccreditation of Healthcare Organizations performance mea-
ures, and these data were available for sites to review and
nalyze in real time. The registry data coordinating center was
utcome Sciences, Inc. (Cambridge, Massachusetts).
Patients were eligible for registry enrollment if they were
18 years of age and the primary reason for their hospital
dmission was new or worsening HF or if they developed
ignificant HF symptoms during their hospitalization, even
f HF was not the reason for their initial admission but was
he primary discharge diagnosis (9). The registry enrolled
onsecutive patients and included patients with left ventric-
lar systolic dysfunction (LVSD), defined as a left ventric-
lar ejection fraction (LVEF)40% or moderate/severe left
entricular dysfunction by qualitative report; those with
reserved systolic function, defined as LVEF 40% or
ualitatively normal left ventricular function; and those
ithout ventricular function measured. Baseline character-
stics, treatment patterns, and in-hospital outcomes were
ollected on all patients participating in the study. Admis-
ion staff, medical staff, or both recorded race/ethnicity,
sually as the patient was registered. Prior studies in patients
ospitalized with HF have suggested differences in charac-
eristics and outcomes on the basis of race/ethnicity. Auto-
ated electronic data checks were used to prevent out-of-
ange entry or duplicate patients. A database audit was
erformed, on the basis of predetermined criteria, of a
andom sample of 5% of the first 10,000 patients verified
gainst source documents (10,11). The protocol was ap-
roved by each participating center’s institutional review
oard or through use of a central institutional review board.
tatistical methods. All statistical analyses were performed
ndependently by the Duke Clinical Research Institute,
urham, North Carolina. Data are reported as mean  SD
or continuous variables or percentages of patients with
onmissing values for categorical variables. A logistic model
as developed to identify significant predictors of in-
ospital mortality. Deaths beyond the first 120 days of
ospitalization were censured. There were 30 patients where
ital status was missing. Forty-five candidate predictor
ariables were considered in the model (Table 1). The final
odel was derived in the population of patients without
issing data for any variable retained in the model (Fig. 1).
hese baseline clinical and treatment factors were applied
ith both stepwise and backward variable selection tech-
iques with a p value of 0.05 as criteria for both entering and
emaining in the model. The restricted cubic spline trans-
ormation method was used to determine the functional
orm for continuous variables. The most common transfor-
ation applied for modeling was piecewise linear splines.
he final model was repeated with generalized estimating
quations to account for the correlation of data within the
ame hospital in the adjusted models. The final model
resented is based on the model including the hospital
ffect. The SAS statistical software, version 8.2 (SAS
nstitute Inc., Cary, North Carolina) was used for all
tatistical analyses.
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July 29, 2008:347–56 Predictors of HF Hospital Mortality in the OPTIMIZE-HF TrialA point scoring system, or nomogram, was developed to
redict in-hospital mortality. This score was calculated from
he 7 most important predictors from the multivariable
andidate Predictors Considered in the Model
Table 1 Candidate Predictors Considered in the Model
Baseline characteristics
Age
Female gender
Race (Caucasian, African American evaluated separately)
Medical history/comorbidities
Smoker within the previous year
Internal cardiac defibrillator
Anemia
Atrial arrhythmia
Coronary artery disease
Cerebrovascular accident or transient ischemic attack
Depression
Insulin-treated diabetes
Noninsulin-treated diabetes
Hyperlipidemia
Hypertension
Liver disease
Chronic obstructive pulmonary disease
Pulmonary hypertension
Prior myocardial infarction
Prior revascularization
Renal disease
Reactive airway disease
Peripheral vascular disease
Thyroid abnormality
Ventricular arrhythmia
Pacemaker
Vital signs/clinical characteristics (at admission)
Weight
Heart rate
Systolic blood pressure
Diastolic blood pressure
HF characteristics/history
Ischemic HF
No known prior HF
HF as primary cause of admission
LVSD
Rales
Lower extremity edema
Laboratory data
Admission serum sodium
Admission serum creatinine
Admission hemoglobin
Admission medications
ACE inhibitor
Aldosterone antagonist
Angiotensin receptor blocker
Beta-blocker
Digoxin
Statin
Diuretic
CE  angiotensin-converting enzyme; HF  heart failure; LVSD  left ventricular systolic
ysfunction.ogistic regression analysis. The score was determined by theegression coefficient and the range of value of each predic-
or (12). We used 200 bootstrap re-samples to evaluate the
eliability of the regression coefficients and the C-statistic
rom the reduced model used to create the nomogram.
inally, a classification and regression tree (CART) analysis
as performed to compare the ability of the logistic regres-
ion model to discriminate mortality compared with this
lternative methodology.
esults
he OPTIMIZE-HF enrollment began in March 2003
nd was completed in December 2004. A total of 48,612
atients were enrolled from 259 hospitals across all regions
f the U.S. Hospitals of all sizes participated in the
PTIMIZE-HF registry, including both academic (48%)
nd community-based (52%) centers. Of participating cen-
ers, 14% perform heart transplantation. The mean age of
he overall cohort was 73 years; 52% of the participants were
omen, and 74% were Caucasian. LVSD was present in
9% of those patients assessed for this variable. The in-
ospital mortality rate was 3.8% (n  1,834), providing an
dequate number of events from which to evaluate predic-
ors. Hospital characteristics, patient clinical characteristics
t admission, and clinical outcomes are reported in Table 2.
f the 18 variables retained in the model, only 3 were
98% or more complete: race, missing in 2.93%; smoking
tatus, missing in 3.59%; and left ventricular systolic func-
ion measured, missing in 15.1%. The overall model was
ased on complete cases of 37,548 patients and 1,217 deaths
Fig. 1).
Figure 1 Cohort Derivation and
Variable Retention for the Risk Model
Diagram showing number of patients, number
of deaths, and variables at each stage in model development
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Predictors of HF Hospital Mortality in the OPTIMIZE-HF Trial July 29, 2008:347–56Univariable predictors of in-hospital mortality are shown in
able 3. On multivariable analysis, 18 of the 45 candidate
ariables were predictive of mortality (Table 4). The C-statistic
or the final model with these variables was 0.77 before
djusting for center effects with generalized estimating equa-
ions. The patient characteristics that were most strongly
redictive of in-hospital mortality included admission serum
reatinine (SCr), admission systolic blood pressure (SBP), and
atient age. In-hospital mortality increased 18% for every 0.3
g/dl increase in SCr up to approximately 3.5 mg/dl; increases
bove 3.5 mg/dl were not associated with incremental risk.
dvanced patient age, per 10-year increase, was associated
ith a 34% higher risk for in-hospital mortality, whereas
ncreased SBP at admission, up to a threshold of approximately
60 mm Hg, was associated with a lower risk of in-hospital
ortality: each 10-mm Hg increase up to 160 mm Hg was
ssociated with a 17% reduction in in-hospital mortality.
Increased risk of in-hospital mortality was associated with
everal comorbid conditions, including liver disease, past
erebrovascular events, peripheral vascular disease, and
ospital Characteristics, Baseline Patient Clinical Characteristics,
Table 2 Hospital Characteristics, Baseline Patient Clinical Cha
Overall Registry
Hospital characteristics, n (%) n  259
Academic hospital 118 (48)
Transplant hospital 34 (14)
Intervention hospital 163 (67)
Patient characteristics n  48,612
Mean age, yrs (SD) 73.2 (14.0)
Male, % 48
Race, % (n  47,189)
Caucasian 74
African American 18
Ischemic etiology, % 46
Hypertensive etiology, % 23
Chronic obstructive pulmonary disease, % 28
Insulin-treated diabetes, % 17
Noninsulin-treated diabetes, % 25
Smoker, % (smoking status documented, n  46,869) 17
Atrial fibrillation, % 31
LVSD, n (% of those with LVF assessed, n  41,267) 20,118 (48.8)
Mean LVEF, % (SD) (n  36,115) 39.0 (17.6)
Rales on admission, % 64
Dyspnea on exertion on admission, % 61
Dyspnea at rest, % 44
Mean systolic blood pressure, mm Hg (SD) 143 (32.9)
Mean heart rate, beats/min (SD) 87 (21.5)
Mean sodium, mEq/l (SD) 137.8 (4.7)
Mean creatinine, mg/dl (SD) 1.8 (1.6)
Mean hemoglobin, g/dl (SD) 12.1 (2.0)
Clinical outcomes n  48,612
Length of stay, days
Mean 5.7
Median 4.0
In-hospital mortality, % 3.8Nonparametric test was used to generate p value.
LVEF  left ventricular ejection fraction; LVF  left ventricular function; other abbreviations as in Tablehronic obstructive pulmonary disease. Of particular interest
as the finding that hyperlipidemia was associated with a
ower risk of in-hospital mortality, particularly because a
tatin or other lipid-lowering therapy was prescribed in only
6% of patients with hyperlipidemia at the time of admis-
ion. Diabetes, gender, and coronary artery disease were not
ignificant predictors of mortality.
Interestingly, patients were at lower risk if HF was
iagnosed for the first time during the index admission.
atients were also significantly more likely to survive the
ospitalization if HF was listed as the primary cause of
dmission. African-American race and a history of smoking
ithin the previous 12 months were factors associated with
lower in-hospital mortality risk.
Of note, patients taking an angiotensin-converting
nzyme inhibitor or beta-blocker at the time of admission
aced lower risk of in-hospital mortality, whereas other
edications including digoxin, angiotensin-receptor
locker, statin, and diuretics did not significantly predict
ortality.
Clinical Outcomes
ristics, and Clinical Outcomes
Patients Surviving
Hospital Stay
Patients Dying During
Hospital Stay
p Value for
Surviving vs. Dying
n  46,778 n  1,834
73.0 (14.0) 78.5 (11.8) 0.0001*
48 51 0.0284
0.0001
74 83
18 10
46 49 0.0067
23 16 0.0001
27 32 0.0001
17 16 0.4364
25 24 0.1929
17 11 0.0001
31 35 0.0002
19,336 (48.5) 782 (56.2) 0.0001
39.1 (17.6) 36.3 (18.3) 0.0001*
64 68 0.0021
62 50 0.0001
44 51 0.0001
143 (32.8) 125 (30.7) 0.0001*
87 (21.4) 89 (22.7) 0.0001*
137.8 (4.7) 136.6 (5.7) 0.0001*
1.7 (1.6) 2.2 (1.6) 0.0001*
12.1 (2.0) 11.7 (2.1) 0.0001*
n  46,778 n  1,834
0.4562*
5.7 4.1
4.0 4.0
— —and
racte1.
S
w
2
w
t
n
(
v
t
f
c
o
p
o
m
F
i
t
U
C ons as
I
T
351JACC Vol. 52, No. 5, 2008 Abraham et al.
July 29, 2008:347–56 Predictors of HF Hospital Mortality in the OPTIMIZE-HF TrialIn-hospital mortality was evaluated by admission SCr and
BP subgroups. Mortality was lowest (2.5%) in patients
ith SBP readings above 100 mm Hg and SCr values below
.0 mg/dl. The highest mortality was evident in patients
ith low SBP and elevated SCr (Fig. 2).
The risk-prediction nomogram generated from the mul-
ivariable model is displayed in Table 5. The risk prediction
omogram is also available at the OPTIMIZE-HF website
13). This model was based on complete cases for the 7
ariables: 40,201 patients, and 1,337 fatal events. From this
nivariable Predictors
Table 3 Univariable Predictors
Predictor
Age: per 10-yr increase
African American
Heart rate: per 10 beats/min increase between 65 and 110 beats/min
SBP: per 10-mm Hg increase up to 160 mm Hg
Diastolic blood pressure: per 10-mm Hg increase up to 100 mm Hg
Sodium: per 3-mEq/l decrease; above 140 mEq/l
Sodium: per 3-mEq/l decrease; below 140 mEq/l
SCr: per 0.3-mg/dl increase up to 3.5 mg/dl
Cause of admission: HF vs. other
Cerebrovascular accident/transient ischemic attack (prior)
Hyperlipidemia
Liver disease
Smoker within past year
Chronic obstructive pulmonary disease
Peripheral vascular disease
No known HF before this admission
LVSD
ACE inhibitor at admission
Beta-blocker at admission
I  confidence interval; SBP  systolic blood pressure; SCr  serum creatinine; other abbreviati
n-Hospital Mortality Model
Table 4 In-Hospital Mortality Model
Variable
SCr: per 0.3-mg/dl increase up to 3.5 mg/dl
SBP: per 10-mm Hg increase up to 160
Age: per 10-yr increase
Heart rate: per 10 beats/min increase between 65 and 110 beats/min
Sodium: per 3-mEq/l decrease below 140 mEq/l
Sodium: per 3-mEq/l decrease above 140 mEq/l
HF as primary cause of admission
Liver disease
Prior cerebrovascular accident/transient ischemic attack
Peripheral vascular disease
Diastolic blood pressure: per 10-mm Hg increase up to 100 mm Hg
Hyperlipidemia
Smoker within past year
No known HF before this admission
African American
LVSD
Chronic obstructive pulmonary disease
ACE inhibitor at admission
Beta-blocker at admissionhe model was based on complete cases of 37,548 patients and 1,217 deaths.
Abbreviations as in Tables 1 and 3.able or the website, one can use common variables collected
or a patient at baseline. From each of these variables, a score
an be calculated that is directly associated with the probability
f in-hospital mortality (Fig. 3). For example, a 50-year-old
atient admitted for HF with a heart rate of 82 beats/min, SBP
f 91 mm Hg, serum sodium of 126 mmol/l, and SCr of 1.5
g/dl would have a score of 9  2  14  7  7  0  39.
rom Figure 3, a score of 39 is associated with a probability of
n-hospital mortality of 4%. This model had good discrimina-
ion and excellent reliability, as seen in Figure 4. The boot-
Ratio 95% CI Wald Chi-Square p Value
01 1.346–1.459 269.6717 0.0001
12 0.439–0.597 72.6897 0.0001
94 1.062–1.127 35.5163 0.0001
67 0.752–0.782 686.0916 0.0001
25 0.703–0.747 435.2111 0.0001
11 0.749–0.879 26.3194 0.0001
45 1.208–1.283 201.1702 0.0001
68 1.150–1.186 394.9925 0.0001
56 0.578–0.743 43.6791 0.0001
28 1.179–1.495 21.8900 0.0001
08 0.636–0.788 39.7312 0.0001
93 1.345–2.391 15.8274 0.0001
90 0.505–0.690 43.9171 0.0001
33 1.115–1.363 16.5641 0.0001
14 1.251–1.597 30.7676 0.0001
24 0.434–0.632 45.7773 0.0001
66 1.226–1.522 32.0067 0.0001
00 0.633–0.774 48.5991 0.0001
06 0.643–0.776 52.3759 0.0001
in Table 1.
Chi-Square Odds Radio 95% CI p Value
35.5 1.18 1.16–1.20 0.0001
07.0 0.83 0.80–0.86 0.0001
08.5 1.34 1.26–1.41 0.0001
55.1 1.18 1.13–1.24 0.0001
39.1 1.15 1.10–1.20 0.0001
6.63 0.87 0.78–0.97 0.0100
10.7 0.72 0.60–0.88 0.0011
11.5 2.33 1.43–3.80 0.0007
18.6 1.37 1.19–1.58 0.0001
12.9 1.32 1.13–1.54 0.0003
12.9 0.90 0.85–0.95 0.0003
11.1 0.80 0.71–0.91 0.0009
12.5 0.70 0.58–0.85 0.0004
10.5 0.65 0.51–0.85 0.0012
11.1 0.71 0.57–0.87 0.0009
14.0 1.28 1.13–1.46 0.0002
6.32 1.19 1.04–1.35 0.0120
7.67 0.84 0.75–0.95 0.0056
17.3 0.77 0.68–0.87 0.0001Odds
1.4
0.5
1.0
0.7
0.7
0.8
1.2
1.1
0.6
1.3
0.7
1.7
0.5
1.2
1.4
0.5
1.3
0.7
0.7Wald
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Predictors of HF Hospital Mortality in the OPTIMIZE-HF Trial July 29, 2008:347–56trapped re-sampling indicated that discrimination remained
igh with a C-statistic of 0.753 (95% confidence interval:
.741 to 0.765).
Furthermore, this nomogram was applied to admission
ata for patients hospitalized with acute decompensated HF
nd enrolled in a previously published randomized con-
rolled trial of acutely decompensated HF, the OPTIME-
HF trial (14). There were 28 in-hospital deaths among
he 937 patients included in the trial. The OPTIMIZE-HF
omogram performed well in this highly selected patient
opulation, predicting an in-hospital mortality rate of 2.91%
ompared with an observed rate of 2.99%, with a C statistic of
.756. The model was further validated with ADHERE
Acute Decompensated Heart Failure National Registry) data
ith 181,830 HF patient hospitalization episodes (4,649 in-
Figure 2 In-Hospital Mortality by SCr and SBP
The relationship between serum creatinine (SCr) and systolic blood
pressure (SBP) as measured at hospital admission and in-hospital mortality.
isk-Prediction Nomogram
Table 5 Risk-Prediction Nomogram
Age,
yrs Score
Heart Rate,
beats/min Score
SBP,
mm Hg Score
Sodium,
mEq/l
20 0 65 0 50 22 110
25 2 70 1 60 20 115
30 3 75 1 70 18 120
35 5 80 2 80 16 125
40 6 85 3 90 14 130
45 8 90 4 100 12 135
50 9 95 4 110 10 140
55 11 100 5 120 8 145
60 13 105 6 130 6 150
65 14 110 6 140 4 155
70 16 150 2 160
75 17 160 0 165
80 19 170
85 20
90 22
95 24he nomogram was based on 40,201 patients and 1,337 fatal events.
Abbreviations as in Tables 1 and 3.ospital deaths) at 285 hospitals from October 2001 to May
005. The OPTIMIZE-HF model performed well in this
opulation with a C statistic of 0.746. Finally, a CART
nalysis was performed on the OPTIMIZE-HF data and
ielded SBP, SCr, age, and heart rate as the variables most
iscriminative for in-hospital mortality. The C statistic of this
ART model was 0.683, indicating the OPTIMIZE-HF
ogistic regression model and nomogram had superior capabil-
ty in predicting mortality.
iscussion
hese data from OPTIMIZE-HF further reinforce that
atients hospitalized with worsening symptoms of HF face
high risk of mortality and provide new insight into the
redictors of in-hospital mortality among a representative
F patient population. We observed both similarities and
ifferences between our findings and those of other pub-
ished risk models (Table 6). Few risk-prediction models
ave been developed specifically with the hospitalized HF
opulation. With the exception of OPTIMIZE-HF and
he ADHERE, the majority of these models were devel-
ped with relatively small samples and in highly selected
roups of HF patients. In addition, previous data were
ollected in the early to late 1990s and might not accurately
eflect current trends in HF management or outcomes.
The OPTIMIZE-HF registry is most comparable to the
DHERE registry in terms of its scope and temporal
elevance. Although the in-hospital mortality rates for
DHERE (4%) and OPTIMIZE-HF (3.8%) are remark-
bly similar (15), ADHERE used the CART analytic
ethod to determine the best predictors of in-hospital
ortality and OPTIMIZE-HF used logistic regression.
he 3 factors most predictive of mortality in ADHERE
core
SCr,
mg/dl Score
Primary Cause
of Admission Score LVSD Score
13 0 0 HF 0 No 0
11 0.5 2 Other 3 Yes 1
9 1 5
7 1.5 7
4 2 10
2 2.5 12
0 3 15
2 3.5 17
4
6
8
10
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July 29, 2008:347–56 Predictors of HF Hospital Mortality in the OPTIMIZE-HF Trialere blood urea nitrogen, SBP, and SCr (16). These factors
lso were identified in OPTIMIZE-HF as significant
redictors, with the exception of blood urea nitrogen, which
as not collected in the OPTIMIZE-HF database. Several
ther predictors were identified as well, as noted in the
receding text.
The in-hospital mortality predictors detected in
PTIMIZE-HF are consistent with other published re-
orts in both hospitalized patients and those with chronic
table HF. Increased SCr, older age, increased heart rate,
iver disease, cerebrovascular disease, low SBP, and low
erum sodium have all been associated with in-hospital
ortality (2–4,6,7). The findings of the OPTIMIZE-HF
odel confirm the relevance of these variables as prognostic
actors with a population representative of the current HF era.
Several variables were noted to have a significant differ-
nce in slope beyond certain cutoff points. Increased SCr
as associated with higher mortality up to the level of 3.5
g/dl. Beyond this level, no incremental risk was evident. A
imilar relationship was reported in ADHERE where pa-
ients with estimated glomerular filtration rate in the 15 to
9 ml/min/1.73 m2 range had higher in-hospital mortality
7.6%) than patients with estimated glomerular filtration
ate 15 ml/min/1.73 m2 (6.5%) (17). A difference in slope
as also noted for SBP: as SBP increased, mortality risk
ecreased. This finding was present up to an SBP of 160
m Hg, and there was no incremental benefit of increases
eyond this point. Our model did not detect excess risk
ssociated with higher SBP, but the number of patients with
eadings above this level might not have been large enough
o detect any evidence of this association. Patients hospital-
zed with HF and elevated SBP might have greater myo-
ardial reserve and thus be at lower short-term mortality
Figure 3 Association Between Risk
Prediction Score and Probability of Death
The risk of in-hospital mortality as a function
of the risk prediction nomogram score from Table 5.isk. In addition, it might be easier to stabilize and restoreompensation in these patients compared with those admit-
ed with lower SBP.
The fact that hyperlipidemia and smoking within the
revious year were associated with lower in-hospital mor-
ality risk might be considered counterintuitive. Only
lightly more than one-half (66%) of patients with a
iagnosis of hyperlipidemia were treated with statins or
ther lipid-lowering therapy at the time of hospital admis-
ion. However, a number of prior studies have demonstrated
n inverse relationship between total cholesterol levels and
ortality in patients with pre-existing chronic HF (18,19).
his is the first study, to our knowledge, suggesting that a
istory of hyperlipidemia is associated with lower mortality
mong hospitalized HF patients. Hyperlidiemia might be a
arker of less-severe HF or a potential mediator of im-
roved outcome as previously suggested (18,19). The lipid
rofile at the time of the admission was not collected and, as
result the relationship between the actual lipid parameters
nd in-hospital mortality, could not be determined. Al-
hough cigarette smoking is clearly established as a major
odifiable risk factor for cardiovascular disease, current or
ecent smoking has previously been reported to be associ-
ted with lower short-term mortality risk among patients
ospitalized with acute myocardial infarction or stroke (the
o-called smoker’s paradox) (20,21). The current findings
uggest that current or recent smoking might precipitate
ospitalization in patients with lesser underlying HF disease
everity and as a result lower in-hospital mortality risk. This
nding requires replication and further analysis.
Patients with a de novo HF hospitalization were found to
e at significantly lower risk for in-hospital mortality, even
fter adjustment for other prognostic variables. Recent
tudies have suggested that prior hospitalization for HF
onfers a significantly increased risk of subsequent death
22,23). In a large community-based study, patients with first
ospitalization for HF were at lower risk for mortality and each
Figure 4 Predicted Versus Actual In-Hospital Mortality
The reliability plot for the OPTIMIZE-HF (Organized Program to Initiate Lifesaving
Treatment in Hospitalized Patients with Heart Failure) registry nomogram with
95% confidence intervals is shown.
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urther increased mortality (23). The current study extends
hese findings and demonstrates that first hospitalization for
F is associated with lower in-hospital mortality, independent
f other prognostic variables. African-American patients hos-
italized with HF were found to be at lower risk for in-hospital
ortality, confirming prior observations (24,25). Although this
ight reflect the younger age of African-American patients,
hese findings persisted after multivariable adjustment. Re-
idual confounding by measured and unmeasured variables
hould be considered in accounting for these observations.
omparison With Other Prediction Models
Table 6 Comparison With Other Prediction Models
Reference Data Source n Time Period
Brophy et al. (4) Registry 153 Late 1980s t
early 1990
Clinical Quality
Improvement
Network
Investigators (6)
Registry 4,606 1992–1993
EFFECT, Lee et al. (7) Registry 4,031 1997–2001
Aronson et al. (3) Clinical trial 541 1996–1999
OPTIME-CHF, Felker
et al. (2)
Clinical trial 949 1997–1999
ADHERE, Adams
et al. (15)
Registry 33,046 (derivation cohort);
32,229 (validation cohort)
2001–2003
OPTIMIZE-HF Registry 48,612 2003–2004
DHERE Acute Decompensated Heart Failure National Registry; CVA/TIA cerebrovascular accid
ew York Heart Association; OPTIME-CHF  Outcomes of a Prospective Trial of Intravenous Milrinowever, differences in the pathophysiology of HF and/or Sesponse to treatment in African Americans also remain a
otential explanation.
Of particular interest in this OPTIMIZE-HF analysis is
he finding that treatment with an angiotensin-converting
nzyme inhibitor or beta-blocker at the time of hospital
dmission predicted improved in-hospital survival. Al-
hough the mortality benefit of these therapies has been
roven in numerous randomized, clinical HF trials, thera-
ies continue to be underused in eligible patients, depriving
hem of potential benefits. This finding in OPTIMIZE-HF
omplements an analysis of the ESCAPE (Evaluation
Mortality Rate Higher Mortality Risk Lower Mortality Risk
1% in 47 months Prior admission for HF
Hyponatremia
Intraventricular
conduction delay
Cumulative intravenous
furosemide dose
9% in-hospital Age
Use of magnesium
Use of nitrates
ACE inhibitors
Warfarin
Aspirin
Beta-blockers
Calcium-channel blockers
.9% in-hospital/
derivation cohort;
.2% in-hospital/
validation cohort;
0.4%–10.7% at
30 days;
0.5%–32.9% at 1 yr
Age
Increased respiratory rate
Hyponatremia
Low hemoglobin
Increased blood urea
nitrogen
Cerebrovascular disease
Dementia
Chronic obstructive
pulmonary disease
Cirrhosis
Cancer
Increased SBP
3%, mean follow-up
343 ( 185) days
Blood urea nitrogen
Blood urea nitrogen/
SCr ratio
Heart rate
Ischemic etiology
Age
Hyponatremia
Increased SBP
.6% 60-day mortality Age
NYHA functional class IV
vs. I–III
Blood urea nitrogen
Increased SBP
Increased serum sodium
.2% (derivation);
% (validation)
in-hospital mortality
Blood urea nitrogen
above 43
SCr 2.75
SBP 115 mm Hg
.8% in-hospital
mortality
Increased SCr
Low serum sodium
Age
Increased heart rate
Liver disease
Prior CVA/TIA
Peripheral vascular
disease
Caucasian
LVSD
Chronic obstructive
pulmonary disease
Increased SBP
Increased serum sodium
Increased diastolic blood
pressure
Hyperlipidemia
Smoking within previous year
No known HF before
admission
HF as primary cause of
admission
ransient ischemic attacks; EFFECT Enhanced Feedback for Effective Cardiac Treatment; NYHA
Exacerbations of Chronic Heart Failure; other abbreviations as in Tables 1 and 3.o
s
6
1
8
8
1
3
3
9
4
4
3tudy of Congestive Heart Failure and Pulmonary Artery
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July 29, 2008:347–56 Predictors of HF Hospital Mortality in the OPTIMIZE-HF Trialatheterization Effectiveness) dataset, showing in a smaller
linical trial population that beta-blocker use before and
uring HF hospitalization was associated with improved
ost-discharge outcomes (26). Efforts should continue to
ocus on ensuring that all eligible patients are treated with
hese important therapies.
Easily accessible assessments such as SCr, blood pressure,
ge, heart rate, sodium, LVSD, and cause of admission can
e entered into a print or internet access version of the
omogram to accurately predict in-hospital mortality risk.
he unique contribution of this OPTIMIZE-HF analysis
s the development of a scoring system and nomogram that
imultaneously integrates these parameters—known in vir-
ually all HF patients at the time of admission—and
ccurately predicts individual patient risk for in-hospital
ortality. Applied clinically, such an assessment could
eadily identify high-risk patients who might require inten-
ive monitoring, early referral to advanced HF management
eams with left ventricular assist device/transplant capabil-
ty, or if appropriate referral to hospice care. Alerting
hysicians to the existence of this risk is a strategy with the
otential to help them target interventions to reduce short-
erm mortality in this population. Having performed well in
oth HF clinical trial populations and real-world registry
atasets, this model might be particularly useful in HF
linical trial design and subsequent development of im-
roved in-hospital HF treatments and treatment strategies.
n essential next step is to study whether prospective
pplication of the risk prediction score will favorably impact
atient care and clinical outcomes.
tudy limitations. These findings should be considered in
he context of several limitations. This model reports
n-hospital mortality only and was not validated for post
ischarge outcomes. Other factors might be of prognostic
alue for postdischarge mortality or rehospitalization. The
PTIMIZE-HF registry was not a prospective, random-
zed trial. Unmeasured variables might have been present
hat could have influenced the findings. The mortality risk
ight have been influenced by other factors that were not
easured, documented, included in the database, or con-
idered as candidate variables. The model can only be
pplied to patients in whom the model variables have been
ssessed. Furthermore, these data do not define cause-and-
ffect relationships. Rather, they identify associations be-
ween patient variables and in-hospital mortality. Due to
he large number of patients included in OPTIMIZE-HF,
ome observations might be statistically significant but not
ecessarily clinically relevant.
onclusions
espite numerous advances in the treatment of chronic HF,
he OPTIMIZE-HF registry provides further evidence
howing that patients still face a high risk of mortality when
ospitalized for worsening HF. These results suggest that
he in-hospital mortality risk for hospitalized HF patients Lan be reliably identified with demographic data, vital signs,
nd laboratory data obtained on hospital admission. Admis-
ion SBP, serum creatinine, and patient age are strong
ndependent predictors of in-hospital mortality. The
PTIMIZE-HF risk tool provides clinicians with a well-
alidated bedside tool for in-hospital mortality risk stratifi-
ation. Application of the risk-prediction score might help
dentify patients at high risk for in-hospital mortality who
ight benefit from aggressive monitoring and intervention.
here is a need for further efforts to define and stratify
ortality risk for patients hospitalized for HF.
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